New clinical trial designs for HIV vaccine evaluation

Current Opinion in HIV and AIDS

Volumn 8, Issue 5, 2013, Pages 437-442

  Moodie, Zoe ^a   Janes, Holly ^a,b   Huang, Yunda ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

HIV prevention; immune correlates; multiarm trial; vaccine efficacy

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO;

CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INFECTION PREVENTION; PRIORITY JOURNAL; REVIEW; STUDY DESIGN; VACCINE PRODUCTION;

EID: 84883461399     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328363d46a     Document Type: Review

References (32)

1. Pitisuttithum P, Gilbert PB, Gurwith M, et al. Randomized, placebo-controlled efficacy trial of a bivalent rgp120 HIV-1 vaccine among injecting drug users in Bangkok, Thailand. J Infect Dis 2006; 194:1661-1671.
2. Flynn NM, Forthal DN, Harro CD, et al. Placebo-controlled phase 3 trial of recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191:654-665.
3. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372: 1881-1893.
4. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-2220.
5. Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366:1275-1286.
6. Corey L, Nabel GJ, Dieffenbach C, et al. HIV-1 vaccines and adaptive trial designs. Sci Transl Med 2011; 3:79ps13.
7. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-1174.
8. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363: 2587-2599.
9. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367: 399-410.
10. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367:423-434.
11. Saunders KO, Rudicell RS, Nabel GJ. The design and evaluation of HIV-1 vaccines. AIDS 2012; 26:1293-1302.
12. Gilbert PB, Grove D, Gabriel E, et al. A Sequential Phase 2b trial design for evaluating vaccine efficacy and immune correlates for multiple HIV vaccine regimens. Stat Commun Infect Dis 2011; 3:1037.
13. Gray GE, Allen M, Moodie Z, et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a doubleblind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis 2011; 11:507-515.
14. Mehrotra DV, Li X, Gilbert PB. A comparison of eight methods for the dualendpoint evaluation of efficacy in a proof-of-concept HIV vaccine trial. Biometrics 2006; 62:893-900.
15. Rida W, Fast P, Hoff R, Fleming T. Intermediate-size trials for the evaluation of HIV vaccine candidates: a workshop summary. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:195-203.
16. Burton DR, Desrosiers RC, Doms RW, et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004; 5:233-236.
17. Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 2008; 47:401-409.
18. Burton DR, Desrosiers RC, Doms RW, et al. Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science 2004; 303:316.
19. Fauci AS. The AIDS epidemic: considerations for the 21st century. N Engl J Med 1999; 341:1046-1050.
20. Clements-Mann ML. Lessons for AIDS vaccine development from non-AIDS vaccines. AIDS Res Hum Retroviruses 1998; 14 (Suppl 3):S197-S203.
21. Clements-Mann ML, Weinhold K, Matthews TJ, et al. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis 1998; 177:1230-1246.
22. Burton DR, Desrosiers RC, Johnson PR, Koff WC. An AIDS vaccine: no time to give up. Lancet 2004; 364:1938.
23. Haynes BF, Pantaleo G, Fauci AS. Response: HIV quasispecies and resampling. Science 1996; 273:416a.
24. Baker BM, Block BL, Rothchild AC, Walker BD. Elite control of HIV infection: implications for vaccine design. Expert Opin Biol Ther 2009; 9:55-69.
25. Plotkin SA, Gilbert PB. Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis 2012; 54:1615-1617.
26. Follmann D. Augmented designs to assess immune response in vaccine trials. Biometrics 2006; 62:1161-1169.
27. Rolland M, Gilbert P. Evaluating Immune Correlates in HIV Type 1 Vaccine Efficacy Trials: What RV144 May Provide. AIDS Res Hum Retroviruses 2012; 28:400-404.
28. Huang Y, Gilbert PB, Wolfson J. Design and estimation for evaluating principal surrogate markers in vaccine trials. Biometrics 2013; doi: 10.1111/biom. 12014. Epub ahead of print.
29. Excler JL, Rida W, Priddy F, et al. AIDS vaccines and preexposure prophylaxis: is synergy possible? AIDS Res Hum Retroviruses 2011; 27:669-680.
30. Kersh EN, Adams DR, Youngpairoj AS, et al. T cell chemo-vaccination effects after repeated mucosal SHIV exposures and oral preexposure prophylaxis. PLoS One 2011; 6:e19295.
31. Janes H, GilbertPB, Sobieszczyk M, et al. In pursuit of an HIV vaccine: designing efficacy trials in the context of partially effective non-vaccine prevention modalities. AIDS Res Hum Retroviruses 2013; Epub ahead of print.
32. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. NEJM 2010; 363:2587-2599.